The pharmacological approach to prevent the secondary degeneration in spinal cord injury has been flanked by cellular therapy. The use of stem cells has also been considered as a new tool for treating injury in the cord. Recent evidences have shown that amniotic fluid, that contains differentiated and undifferentiated cells arising from all three germ layers, may be a novel source of stem cells for therapeutic transplantation. The main goal of this study was to characterize human cells isolated from the third trimester amniotic fluid as new therapeutic cells in various diseases such as spinal cord injury. We isolated several different populations of adherent cells from nine amniotic fluid samples. Some of these different cell cultures has been studied for in vitro proliferation potential and for expression profile by immunocytochemistry and cytofluorimetry. In particular three culture where deeply investigated and two of them showed a noticeable expression of adult mesenchymal markers (CD146-, CD73+, CD105+, CD90+) directed to the muscle-neural lineage (CD146-, NG2+, CD56+) (#3.5). One of them also express CD117 (#3.6). Another culture showed a mesenchymal phenotype directed to the perivascular lineage (#1). We used these cells to transplant spinal cord injured mice. After intravenous transplantation only the cell cultures #3.6 and #3.5 induced increased recovery of hindlimb function, whereas cell cultures #1 failed. The animals transplanted with #3.6 cells showed a better preservation of ventral myelin at the lesion site than PBS treated mice. Furthermore the number of macrophages and neutrophils was much lower in these transplanted animals when compared to vehicle treated mice. These results suggest that the administration of amniotic fluid derived cells with a muscle-neural phenotype attenuates secondary degeneration by reducing the cellular component of the post-trauma neuroinflammatory reaction
PHENOTYPICAL CHARACTERIZATION OF THIRD TRIMESTER HUMAN AMNIOTIC FLUID CELLS WITH POTENTIAL FOR THERAPY IN NEURODEGENERATIVE DISORDERS / D. Cigognini, E. Nicora, E. Ripamonti, R. Adami, S. Abrignani, M. Moro, P. Rebulla, A.M. Di Giulio, D. Bottai, A. Gorio - In: ABSTRACT BOOK of the 3rd meeting on the Molecular Mechanisms of Neurodegeneration / [a cura di] Dr. Angelo Poletti Dr. Elena Cattaneo Dr. Franco Taroni. - [s.l] : null, 2009 May 10. (( Intervento presentato al 4. convegno Molecular Mechanisms of Neurodegeneration tenutosi a Milano nel 2009.
PHENOTYPICAL CHARACTERIZATION OF THIRD TRIMESTER HUMAN AMNIOTIC FLUID CELLS WITH POTENTIAL FOR THERAPY IN NEURODEGENERATIVE DISORDERS
D. Cigognini;E. Nicora;R. Adami;S. Abrignani;A.M. Di Giulio;D. Bottai;A. Gorio
2009
Abstract
The pharmacological approach to prevent the secondary degeneration in spinal cord injury has been flanked by cellular therapy. The use of stem cells has also been considered as a new tool for treating injury in the cord. Recent evidences have shown that amniotic fluid, that contains differentiated and undifferentiated cells arising from all three germ layers, may be a novel source of stem cells for therapeutic transplantation. The main goal of this study was to characterize human cells isolated from the third trimester amniotic fluid as new therapeutic cells in various diseases such as spinal cord injury. We isolated several different populations of adherent cells from nine amniotic fluid samples. Some of these different cell cultures has been studied for in vitro proliferation potential and for expression profile by immunocytochemistry and cytofluorimetry. In particular three culture where deeply investigated and two of them showed a noticeable expression of adult mesenchymal markers (CD146-, CD73+, CD105+, CD90+) directed to the muscle-neural lineage (CD146-, NG2+, CD56+) (#3.5). One of them also express CD117 (#3.6). Another culture showed a mesenchymal phenotype directed to the perivascular lineage (#1). We used these cells to transplant spinal cord injured mice. After intravenous transplantation only the cell cultures #3.6 and #3.5 induced increased recovery of hindlimb function, whereas cell cultures #1 failed. The animals transplanted with #3.6 cells showed a better preservation of ventral myelin at the lesion site than PBS treated mice. Furthermore the number of macrophages and neutrophils was much lower in these transplanted animals when compared to vehicle treated mice. These results suggest that the administration of amniotic fluid derived cells with a muscle-neural phenotype attenuates secondary degeneration by reducing the cellular component of the post-trauma neuroinflammatory reaction
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
